Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future

Richard Paulson, President and Chief Executive Officer of Karyopharm

“Following a comprehensive review of available alternatives, we believe this process provides a clear framework to pursue a value maximizing transaction for our stakeholders while continuing our important work of advancing therapies for patients with multiple myeloma and myelofibrosis”

Richard Paulson, President and Chief Executive Officer of Karyopharm

“We are pleased to have signed an agreement with Ayrmid, a company committed to advancing meaningful therapies for patients with hematological disorders.”

Richard Paulson, President and Chief Executive Officer of Karyopharm

“Ayrmid's proposal underscores the strategic interest in our programs and establishes a strong foundation as we move through this process designed to maximize value.”

Richard Paulson, President and Chief Executive Officer of Karyopharm

“Throughout, we will remain focused on supporting our employees, maintaining continuity across the business, and advancing our mission to improve the lives of patients.”

Dr. Joe Wiley, Chairman and CEO of Ayrmid

“We see a strong strategic fit between Ayrmid and Karyopharm, with complementary portfolios, established commercial capabilities and a shared commitment to addressing significant unmet needs in hematology.”

Dr. Joe Wiley, Chairman and CEO of Ayrmid

“We see considerable potential in Karyopharm's marketed products, development pipeline and experienced team, and believe that, together, we can build a broader, stronger commercial-stage hematology business with meaningful opportunities for future growth.”

Dr. Joe Wiley, Chairman and CEO of Ayrmid

“Subject to the successful completion of the transaction, we look forward to working with the Karyopharm team to realize that potential and continue delivering important therapies to patients in need.”